Mutational Signature Profiling & Exposure Attribution Service
Creative Biolabs' service transforms raw genomic data into high-value intelligence, directly informing your drug development and diagnostic strategies. We provide the quantitative clarity needed to understand the "why" behind every tumor mutation, translating directly into actionable preclinical insights. By integrating advanced sequencing with proprietary bioinformatics, we clarify the precise functional impact of somatic and germline alterations. This deep understanding enables accurate patient stratification, accelerates the identification of novel therapeutic targets, and validates companion diagnostics, ensuring your research leads to successful personalized oncology outcomes.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Scientific Imperative: Deconstructing Cancer's History
Cancer is fundamentally a disease of the genome, where the therapeutic challenge lies in understanding the origins of mutations. Mutational signatures are the distinct patterns of DNA damage—the "scars" left behind in the tumor's genome—caused by specific endogenous (e.g., DNA repair errors) or exogenous (e.g., UV radiation, toxins) processes. A tumor's mutational spectrum is typically a superimposition of several such damaging processes. Our service provides comprehensive analysis across all known mutation types, including single-base substitutions (SBS) categorized by 96 trinucleotide contexts, double-base substitutions (DBS), and small insertions and deletions (ID).
Key Problem-Solving Capabilities & Deliverables
Precision Biomarker Discovery
We identify and quantify specific signatures (e.g., SBS3 for homologous recombination deficiency, or homologous recombination deficiency) that are predictive of response to targeted therapies like PARP inhibitors, streamlining patient selection.
Enhanced Liquid Biopsy Sensitivity
Our specialized pipeline is optimized to detect and quantify signature activity even in circulating cell-free DNA (cfDNA) with extremely low mutant allele fractions, supporting sensitive early detection and MRD monitoring.
Molecular Epidemiology
Accurately quantify the proportional contribution of environmental and lifestyle factors (e.g., tobacco-related SBS4, UV-related SBS7) in clinical cohorts, essential for risk assessment and targeted prevention strategies.
Intra-Tumor Heterogeneity Mapping
We map "changepoints"—regional shifts in signature activity across the genome—to identify subclonal expansion and localized processes that drive therapeutic resistance.
Preclinical Trial Homogeneity
Use signature attribution to ensure your preclinical trial cohorts are biologically uniform, reducing noise and improving the statistical power of your results.
Contact our specialist team today to discuss how precise mutational signature profiling and exposure attribution can be seamlessly integrated into your next oncology project.
Workflow
Our service utilizes a high-performance computational pipeline to guarantee the most robust and biologically plausible attribution results, ensuring clarity from data ingestion to final reporting.
Publication
This study benchmarks 13 tools for mutational signature attribution, introducing a novel algorithm, PASA (presence attribute signature activity). All methods were evaluated on synthetic data spanning three mutation types across nine cancers. Results show PASA and MuSiCal (mutational signature calculator) generally perform best, but tool rankings vary significantly by cancer type, highlighting the inherent challenge of identifying the correct combination of mutational processes. The work provides essential guidance for selecting the most appropriate attribution method based on specific cancer types and research goals.
Fig.1 Reconstructing the mutational spectrum via signature attribution. 1
Why Choose Us?
Creative Biolabs sets the gold standard in mutational signature analysis by providing certainty, precision, and depth that standard bioinformatics tools cannot match. Our computational rigor eliminates the risk of biologically implausible or non-sparse attribution, which is a common failure point in less sophisticated platforms. Our commitment is to deliver not just data, but certainty. By focusing on robust attribution across all signature types (SBS, DBS, ID) and employing superior computational methods validated against industry benchmarks—including the latest challenges in signature fidelity and liquid biopsy sensitivity—we mitigate the risk of false positives and biologically implausible results. We now extend our analysis to the level of genomic dynamics and regional heterogeneity, and the demanding frontier of cell-free DNA analysis.
Partner with Creative Biolabs to transform genomic data into a roadmap for therapeutic success.
FAQs
What is the main advantage of your service compared to publicly available mutational signature tools?
Our core advantage is the use of proprietary, validated algorithms that enforce sparse and biologically plausible solutions. We minimize false positives and maximize confidence in your data, especially for complex or noisy samples like cfDNA.
Do I need to provide whole-genome sequencing (WGS) data, or will whole-exome sequencing (WES) suffice?
While WGS provides the most comprehensive data for robust signature analysis, we are highly proficient at extracting reliable signatures from WES data. However, regional dynamics mapping is best achieved with WGS.
Can your service help me predict if my drug will cause off-target DNA damage?
Yes. By including samples exposed to your compound, we can perform highly sensitive signature analysis to detect and quantify signatures indicative of drug-induced DNA damage. This provides critical, early safety data and mechanistic insights.
Customer Review
-
Improved Therapeutic Insight
We confirmed the HRD status (SBS3 activity) in our cohort with far greater confidence compared to standard gene panel testing, leading to a stronger rationale for our PARP inhibitor trial. - Jian L*
-
Enhanced Liquid Biopsy Performance
The output was remarkably clean and showed strong concordance with expected environmental exposure signatures, a substantial improvement over previous flat-attribution method. – Sarh*B
Related Services
To further accelerate your oncology and diagnostics projects, Creative Biolabs offers several complementary services:
Tumor Profiling for Personalized Cancer Treatment
Creative Biolabs performs tumor profiling using advanced technologies to analyze DNA, RNA, and proteins, providing a molecular profile that guides precise targeted therapies for improved patient outcomes.
Learn More →
Gene-targeting Lineage Tracing Technology Services
Creative Biolabs offers an advanced gene-targeting lineage tracing platform using FLP/FRT, Cre-loxP, and Dre-rox systems for accurate interpretation of tumor cell fate, offering services from fixed-point transformation to GMO construction.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs is your trusted partner for decoding the complex history of cancer. Our mutational signature profiling and exposure attribution service provides unmatched precision in quantifying mutagenic processes (SBS, DBS, ID) and mapping the genomic dynamics that drive tumor evolution, empowering your biomarker discovery and therapeutic development efforts.
Contact Our Team for More Information and to Discuss Your Project.
Reference
-
Jiang, Nanhai, Yang Wu, and Steven G. Rozen. "Benchmarking 13 tools for mutational signature attribution, including a new and improved algorithm." Briefings in Bioinformatics 26.1 (2025): bbaf042. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1093/bib/bbaf042
For Research Use Only | Not For Clinical Use
Download our brochure